Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.
暂无分享,去创建一个
L. Leibovici | E. Goldberg | A. Gafter-Gvili | M. Paul | E. Robenshtok | M. Weinberger | M. Yeshurun
[1] L. Leibovici,et al. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. , 2008, European journal of cancer.
[2] J. Maertens. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies , 2007, European journal of haematology.
[3] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[4] J. Lipton,et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.
[5] A. Glasmacher,et al. Current experience with itraconazole in neutropenic patients: a concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy , 2006 .
[6] Peter G. Pappas,et al. Invasive Fungal Pathogens: Current Epidemiological Trends , 2006 .
[7] E. Thiel,et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] A. Gorelik,et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients , 2006, Bone Marrow Transplantation.
[9] S. Elad,et al. Oral candidiasis prevention in transplantation patients: a comparative study , 2006, Clinical transplantation.
[10] J. Perfect,et al. Non‐comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation , 2006, Transplant infectious disease : an official journal of the Transplantation Society.
[11] D. Benjamin,et al. Safety and Pharmacokinetics of Intravenous Anidulafungin in Children with Neutropenia at High Risk for Invasive Fungal Infections , 2006, Antimicrobial Agents and Chemotherapy.
[12] A. Glasmacher,et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. , 2006, The Journal of antimicrobial chemotherapy.
[13] P. Gøtzsche,et al. Voriconazole versus amphotericin B in cancer patients with neutropenia. , 2006, The Cochrane database of systematic reviews.
[14] C. Viscoli,et al. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin , 2006, British journal of haematology.
[15] E. Estey,et al. Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies , 2006, Antimicrobial Agents and Chemotherapy.
[16] A. Glasmacher,et al. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. , 2006, The Journal of antimicrobial chemotherapy.
[17] M. Falagas,et al. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials , 2005, British journal of haematology.
[18] N. Chao,et al. Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant , 2005, Antimicrobial Agents and Chemotherapy.
[19] W. Sluiter,et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients , 1997, European Journal of Clinical Microbiology and Infectious Diseases.
[20] J. Ninane,et al. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies , 1994, European Journal of Clinical Microbiology and Infectious Diseases.
[21] M. Kalin,et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[22] E. Estey,et al. Intravenous Voriconazole (IV-VORI) Prevents Invasive Fungal Infections (IFI) in Patients (pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS). , 2004 .
[23] N. Callander,et al. Efficacy of Fluconazole Prophylaxis for Autologous Peripheral Blood Stem Cell Transplantation: Results of a Prospective, Randomized, Controlled, Multicenter, Open Label Study. , 2004 .
[24] J. Lipton,et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[25] J. Wingard. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] J. Szer,et al. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.
[27] J. Epstein,et al. Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy , 2004, Supportive Care in Cancer.
[28] W. Leisenring,et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.
[29] H. Kantarjian,et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.
[30] A. Gratwohl,et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients , 1995, Supportive Care in Cancer.
[31] J. Mardiak,et al. Fluconazol plus ofloxacin in prophylaxis of infections in patients with acute leukemia: a comparative study , 1993, Supportive Care in Cancer.
[32] B. Djulbegovic,et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[34] H. Ulmer,et al. Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution , 2003, Annals of Hematology.
[35] M. Territo,et al. Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial , 2003, Annals of Internal Medicine.
[36] Yu Shen,et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction , 2003, Cancer.
[37] C. Beyan,et al. Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[38] M. Asaka,et al. [Effect of prophylaxis against myocosis in patients with hematological malignancy disease: efficacy of dosage of itraconazole]. , 2003, The Japanese journal of antibiotics.
[39] S. D. Mitrokhin. [Itraconazole (Orungal) in the treatment of mycotic infections in oncologic patients]. , 2003, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic].
[40] S. Fook-Chong,et al. Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation , 2002, American journal of hematology.
[41] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[42] E. Bow,et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.
[43] J. L. Goodman,et al. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. , 2002, The American journal of medicine.
[44] T. Calandra,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[45] D. Denning,et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] H. Jürgens,et al. Liposomal amphotericin B for prophylaxis of invasive fungal infections in high‐risk paediatric patients with chemotherapy‐related neutropenia: interim analysis of a prospective study , 2001, Mycoses.
[47] K. Vandewoude,et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. , 2001, The Journal of antimicrobial chemotherapy.
[48] J. Levron,et al. Pharmacokinetics of Itraconazole Oral Solution in Neutropenic Children during Long-Term Prophylaxis , 2001, Antimicrobial Agents and Chemotherapy.
[49] S J Lin,et al. Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] E. Bow,et al. Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. , 2000, The Journal of antimicrobial chemotherapy.
[51] A. Elmaagacli,et al. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination , 2000, Bone Marrow Transplantation.
[52] Y. Kanda,et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients , 2000, Cancer.
[53] H. Prentice,et al. Towards a targeted, risk‐based, antifungal strategy in neutropenic patients , 2000, British journal of haematology.
[54] J. Harousseau,et al. Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B , 2000, Antimicrobial Agents and Chemotherapy.
[55] A. Ganser,et al. Intensive Intravenous Amphotericin B for Prophylaxis of Systemic Fungal Infections , 2000, Chemotherapy.
[56] D. Touw,et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial , 2000, Bone Marrow Transplantation.
[57] R. Collins,et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group , 2000, Bone Marrow Transplantation.
[58] M. Nucci,et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[59] T. Sauerbruch,et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl‐β‐cyclodextrin oral solution or coated‐pellet capsules , 1999, Mycoses.
[60] S. Durrant,et al. A double-blind comparison of fluconazole and nystatin in the prevention of candidiasis in patients with leukaemia , 1999 .
[61] W. Siegert,et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. , 1999, Blood.
[62] H. van Tinteren,et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. , 1999, Journal of clinical pathology.
[63] E. Bow,et al. Randomized Placebo-Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic Therapy , 1999 .
[64] A. Favero,et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[65] M. Okada,et al. Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. , 1999, Drugs under experimental and clinical research.
[66] E. Spasov,et al. Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. , 1999, Folia medica.
[67] H. Prentice,et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. , 1999, British journal of haematology.
[68] S. McCann,et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study , 1999, Bone Marrow Transplantation.
[69] R. Mücke,et al. Fluconazole prophylaxis in patients with head and neck tumours undergoing radiation and radiochemotherapy , 1998, Mycoses.
[70] W. Hiddemann,et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia , 1998, Cancer.
[71] W. Leisenring,et al. The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients , 1998, Medicine.
[72] C. Jacquelinet,et al. Prophylactic use of itraconazole for the prevention of invasive pulmonary aspergillosis in high risk neutropenic patients. , 1998, Leukemia & lymphoma.
[73] B. Kornhuber,et al. Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. , 1997, The Journal of antimicrobial chemotherapy.
[74] S D Walter,et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.
[75] P. Gøtzsche,et al. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia , 1997, BMJ.
[76] N. Kröger,et al. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation. , 1997, Leukemia and Lymphoma.
[77] L. Bergmann,et al. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. , 1996, The Journal of antimicrobial chemotherapy.
[78] G. Ehninger,et al. Fluconazole in the prophylaxis of fungal infection after bone marrow transplantation , 1996, Mycoses.
[79] A. Prentice,et al. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. , 1995, The Journal of antimicrobial chemotherapy.
[80] A. Schaffner,et al. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. , 1995, The Journal of infectious diseases.
[81] B. Hirschel,et al. Antifungal Prophylaxis in Severely Neutropenic Patients: How Much Fluconazole is Necessary? , 1995, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[82] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[83] R. Haznedar,et al. Prophylactic use of fluconazole in neutropenic cancer patients. , 1995, Postgraduate medical journal.
[84] M. Kalin,et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever--preliminary observations from a pilot, exploratory study. , 1995, The Journal of infection.
[85] A. Ibatici,et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. , 1995, Haematologica.
[86] J. Esteve,et al. [Intravenous amphotericin B as prevention of deep mycoses in allogeneic bone marrow transplantation]. , 1994, Medicina clínica (Ed. impresa).
[87] P. Beatty,et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. , 1994, The American journal of medicine.
[88] C. Begg,et al. Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.
[89] T. Barbui,et al. Preventing Fungal Infection in Neutropenic Patients with Acute Leukemia: Fluconazole Compared with Oral Amphotericin B , 1994, Annals of Internal Medicine.
[90] F. Baillie,et al. The effect of fluconazole as prophylaxis for neutropenic patients on the isolation of Candida spp. from surveillance cultures. , 1994, The Journal of antimicrobial chemotherapy.
[91] O. Ringdén,et al. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. , 1994, Transplantation proceedings.
[92] E. Anaissie,et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B , 1994, Cancer.
[93] H. Sakamaki,et al. Prevention of invasive fungal infection during chemotherapy-induced neutropenia in patients with acute leukemia. , 1994, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.
[94] P. Chandrasekar,et al. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. , 1994, Chemotherapy.
[95] P. Chandrasekar,et al. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. , 1994, The Journal of antimicrobial chemotherapy.
[96] A. Goldstone,et al. Early AmBisome in febrile neutropenia in patients with haematological disorders. , 1994, Bone marrow transplantation.
[97] P. Ljungman,et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. , 1993, Bone marrow transplantation.
[98] H. Sakamaki,et al. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy‐induced neutropenic patients with haematological malignancies Vergleichende Studie über , 1993, Mycoses.
[99] T. Yamada,et al. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. , 1993, Internal medicine.
[100] J. Trupl,et al. Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. , 1993, Chemotherapy.
[101] D. Huhn,et al. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis , 1993, Antimicrobial Agents and Chemotherapy.
[102] G. Mufti,et al. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group. , 1993, The Journal of antimicrobial chemotherapy.
[103] H. Horowitz,et al. Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.
[104] P. Ljungman,et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. , 1993, Transplantation proceedings.
[105] J. Raemaekers,et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. , 1993, Leukemia & lymphoma.
[106] J. Wout. Itraconazole in neutropenic patients. , 1992 .
[107] D. Reece,et al. Efficacy of chlorhexidine and nystatin rinses in prevention of oral complications in leukemia and bone marrow transplantation. , 1992, Oral surgery, oral medicine, and oral pathology.
[108] G. Rosner,et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. , 1992, The Journal of infectious diseases.
[109] J. Palmblad,et al. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias , 1992, Journal of internal medicine.
[110] J. L. Goodman,et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.
[111] R. Larson,et al. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. , 1992, Leukemia & lymphoma.
[112] A. Prentice,et al. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. , 1991, The Journal of antimicrobial chemotherapy.
[113] M. Paesmans,et al. Chemoprophylaxis of Fungal Infections in Granulocytopenic Patients Using Fluconazole vs Oral Amphotericin B , 1991 .
[114] M. Rinaldi. Problems in the diagnosis of invasive fungal diseases. , 1991, Reviews of infectious diseases.
[115] J. Verhoef,et al. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia. , 1991, The Journal of antimicrobial chemotherapy.
[116] C. Noguès,et al. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. , 1991, Bone marrow transplantation.
[117] G. Schaison,et al. Prevention of Gram‐positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children , 1990, British journal of haematology.
[118] G. Michelone,et al. Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study. , 1990, Microbiologica.
[119] T. Tsubota,et al. [A co-operative study on prophylactic effect of oral administration of high-dose amphotericin B syrup for systemic fungal infection in patients with hematological neoplasms. Chugoku-Shikoku Study Group of Mycosis with Hematologic Disease]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.
[120] G. Samonis,et al. Prophylaxis of oropharyngeal candidiasis with fluconazole. , 1990, Reviews of infectious diseases.
[121] F. Soriano,et al. Implications of the inoculum effect. , 1990, Reviews of infectious diseases.
[122] H. Mizoguchi,et al. Prophylactic and therapeutic effects of oral administration of amphotericin B in mycosis associated with hematologic diseases. Study Group of Mycosis in Hematologic Disease. , 1990, The Japanese journal of antibiotics.
[123] K. Brammer. Management of fungal infection in neutropenic patients with fluconazole. , 1990, Haematology and blood transfusion.
[124] G. Samonis,et al. Prophylaxis of candidiasis in cancer patients. , 1990, Seminars in oncology.
[125] A. Prentice,et al. Prophylaxis of Fungal Infections with Itraconazole during Remission‐Induction Therapy , 1989, Mycoses.
[126] P. Parikh,et al. Comparison of clotrimazole with nystatin in preventing oral candidiasis in neutropaenic patients. , 1988, The Indian journal of medical research.
[127] J. Wingard,et al. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. , 1987, The American journal of medicine.
[128] R. Abrams,et al. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. , 1987, Archives of internal medicine.
[129] L. G. Malcom,et al. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. , 1987, Cancer investigation.
[130] E. Bottone,et al. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Results of a double-blind study. , 1986, The American journal of medicine.
[131] D. Shepp,et al. Comparative Trial of Ketoconazole and Nystatin for Prevention of Fungal Infection in Neutropenic Patients Treated in a Protective Environment , 1985 .
[132] G. Bodey,et al. Prophylaxis of oropharyngeal candidiasis with clotrimazole. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] J. Anderson,et al. Ketoconazole prophylaxis in patients with solid tumours receiving aggressive immunosuppressive therapy. An open randomized comparison between 200 mg/d and 400 mg/d doses. , 1985, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[134] T. Louie,et al. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. , 1985, Clinical and investigative medicine. Medecine clinique et experimentale.
[135] R. Quintiliani,et al. Treatment and prevention of oropharyngeal candidiasis. , 1984, The American journal of medicine.
[136] R. Fanci,et al. Fungal infections in hematological neoplastic disease: the possibility of chemoprophylaxis. , 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.
[137] E. Estey,et al. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two. , 1984, Archives of internal medicine.
[138] C. Kauffman,et al. Effect of Prophylactic Ketoconazole and Nystatin on Fungal Flora , 1984, Mykosen.
[139] D. Catovsky,et al. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. , 1984, The Journal of hospital infection.
[140] C. Kauffman,et al. Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients. , 1984, Archives of internal medicine.
[141] E. Estey,et al. Infection prophylaxis in acute leukemia , 1984 .
[142] H. Brincker. Prevention of Mycosis in Granulocytopenic Patients with Prophylactic Ketoconazole Treatment/Prophylaktische Mykose‐Behandlung mit Ketoconazol bei granulozytopenischen Patienten , 1983, Mykosen.
[143] J. Klastersky,et al. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. , 1983, European journal of cancer & clinical oncology.
[144] H. Prentice,et al. KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTS , 1982, The Lancet.
[145] T. Suda,et al. [A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: prophylactic effect of oral administration of amphotericin B (author's transl)]. , 1980, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[146] H. Brincker. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study. , 2009, Acta medica Scandinavica.
[147] T. Lister,et al. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acut- leukemia. , 1977, Medical and pediatric oncology.